Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2734921 | Journal of Pain and Symptom Management | 2009 | 7 Pages |
Abstract
Metastatic bone disease is often associated with severe pain in cancer patients, and has become an increasingly important quality-of-life issue. Radionuclides, such as strontium-89 (Sr-89), have provided effective palliation of metastatic bone pain. Although strontium follows the biochemical pathways of calcium in the body, changes in calcium homeostasis related to Sr-89 therapy have rarely been reported. We present a case of a 32-year-old male with poorly differentiated neuroendocrine carcinoma and extensive skeleton metastases who developed profound hypocalcemia after Sr-89 administration.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Masanori Mori, Nada A. Fadul, Eduardo Bruera, Shalini Dalal,